OKYO Pharma Limited: Directorate Change
December 01 2021 - 1:00AM
OKYO Pharma Limited ("OKYO" or the "Company") today announces that
Bernard Denoyer has been appointed as a non-executive director of
the Company with immediate effect.
Bernard F. Denoyer (age: 74)
Bernard F. Denoyer has 49 years of financial
management experience including his service as Senior Vice
President, Finance and Secretary of development stage Synergy
Pharmaceuticals, Inc. (NASDAQ: SGYP) from July 2008 until FDA
approval and his retirement in June 2017.
From January 2004 until January 2013. Mr.
Denoyer concurrently served as Principal Financial Officer of
Synergy’s former parent company, Callisto Pharmaceuticals, Inc.
While with SGYP and CLSP he supported over $500M of public and PIPE
financings with related due diligence, SEC registrations and market
listings.
From October 2000 to December 2003, Mr. Denoyer
was an independent consultant, providing interim CFO and other
services to emerging businesses, including Callisto and certain
portfolio companies of Marsh & McLennan Capital, LLC. From
October 1994 until September 2000, Mr. Denoyer served as Chief
Financial Officer and Senior Vice President of META Group, Inc., an
information technology research company.
Mr. Denoyer earned his CPA with Ernst &
Young in 1975. He received a Masters Certificate of Accounting from
the Kellogg Graduate School of Management in 1974, an MBA in
Finance with honors from Columbia Business School in 1972, and a BA
in Economics from Fairfield University in 1969.
Mr. Denoyer is fluent in French and studied in
Paris at l’Istitut d’Etude Politique et Economique in 1968. He
served in U.S. Army in Vietnam from 1969 to 1971 and has been an
adjunct accounting professor at Fairfield University and the
Marymount College. He is currently serving on the Board of Trustees
for two 501(c)3 not-for-profits, St. Edmunds Retreat, Inc. and
Midwestern Connecticut Council on Alcoholism, Inc.
Mr Denoyer will assume the role chair the
Nomination Committee of the Board from Mr Gabriele Cerrone (who
will continue to serve as a member of the Nomination
Committee).
With immediate effect Willy Simon will assume
the role of senior non-executive and will continue to chair the
Remuneration Committee of the Board.
Gabriele Cerrone, Chairman of OKYO, said, "We
are delighted that Bernard has joined the Board of OKYO. His
expertise will be of great value to us at a very important time for
the group."
There are no other disclosures to make pursuant
to Listing Rule 9.6.13, in respect of Mr Denoyer's appointment.
The person who approved the content of this
announcement for purposes of UK MAR was Dr Gary Jacob, Chief
Executive Officer.
About OKYO
OKYO Pharma Limited (LSE: OKYO) is a life
sciences and biotechnology company admitted to listing on the
standard segment of the Official List of the UK Financial Conduct
Authority and to trading on the Main Market for listed securities
of the London Stock Exchange plc. OKYO is focusing on the discovery
and development of novel molecules to treat inflammatory dry eye
diseases and chronic pain.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS
PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT)
(EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE
PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS
DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC
DOMAIN.
Enquiries:
OKYO Pharma Limited |
Gabriele Cerrone |
+44 (0)20 7382 8300 |
Optiva Securities Limited |
Robert Emmet |
+44 (0)20 3981 4173 |
For further information, please visit the Company's website at
www.okyopharma.com.
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
Historical Stock Chart
From May 2024 to Jun 2024
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
Historical Stock Chart
From Jun 2023 to Jun 2024